neoSurgical Inc. tells us it will host a medical summit in conjunction with Midland Regional Hospital in Ireland later this month. Titled “Port Site Closure, Tissue Healing, and Hernia in Laparoscopic Surgery: The Real Incidence and Consequences,” the event will review clinical findings and focus on those relating to neoSurgical’s own neoClose® port site closure device.
Laparoscopic abdominal surgery requires an abdominal “port site” which must be closed after surgery. Herniation, commonly referred to as trocar site hernia, or TSH, among doctors), can lead to morbidity due to small bowel strangulation, for example, or nerve and vessel entrapment, resulting in infection, bleeding and pain.
neoSurgical® is a commercial-stage company focused on being a global leader in the development of innovative surgical products, one of which is neoClose, a novel port site closure device that is designed to minimise those aforementioned morbidities.
Until 2014, TSH complications were thought to occur at a reported rate of about 1-6% among the six million Lap surgery port sites closed each year. But one groundbreaking clinical study (Comajuncosas, J, et al. Risk factors for umbilical trocar site incisional hernia in laparoscopic cholecystectomy: a prospective 3-year follow-up study. Am J Surg. 2014 Jan;207(1):-6), suggested that nearly 26% of patients were diagnosed with TSHs. Thus, TSHs have been grossly under-diagnosed.
Following this study, a second published study (Scozzari et al. High incidence of trocar site hernia after laparoscopic or robotic Roux-en-Y gastric bypass. SurgEndosc. 2014 Oct;28(10):2890-8), reported a total trocar site hernia rate of 39.3% at three years.
Most recently a third, multi-institutional study (Holihan JL et al. Adverse events after Ventral Hernia repair: The vicious Cycle of complications, JACS 2015) revealed that hernia occurrence can lead to a repetitive cycle of repeat procedures and complications.
The standard for port site closure has hitherto been Closed Loop Suture. Now neoSurgical points us at its neoClose® device which works by the use of what is termed a Vector X closure, approximating the tissue together and tying into place for a secure closure with up to 75% less tension compared to standard closed loop suture.
“neoClose® represents nothing short of a complete paradigm shift for port site closure,” said James A. Greenberg, MD, Chief of the Division of Gynaecology at Brigham and Women’s Faulkner Hospital, and an Associate Professor at Harvard Medical School, in an independent product review (Contemporary OB/GYN Aug 14). “There is nothing like neoClose®,” added Dr. Greenberg.
“The goals of our summit are to discuss recent clinical findings on the incidence of port site hernia, as well as to discuss preclinical and clinical data related to our port site closure device, neoClose, and review the consequences of hernia and recurrent hernias,” said Barry Russell, CEO of neoSurgical®.
Source: neoSurgical, Inc